Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Depreciation and Depletion (2024 - 2025)

Anika Therapeutics (ANIK) has disclosed Depreciation and Depletion for 2 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • Quarterly Depreciation and Depletion rose 16.67% to $1.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.3 million through Dec 2025, up 8.16% year-over-year, with the annual reading at $5.4 million for FY2025, 8.0% up from the prior year.
  • Depreciation and Depletion for Q4 2025 was $1.4 million at Anika Therapeutics, roughly flat from $1.4 million in the prior quarter.
  • The five-year high for Depreciation and Depletion was $1.4 million in Q3 2025, with the low at $1.2 million in Q1 2024.